Salicylic Acid
Active ingredient · 2 therapeutic classes
Sold as Kingskin · Acne Dots · Compound W · Quick Action · Wart Removers
- Drug class
- Other Antifungals For Topical Use
- Availability
- Prescription and OTC
- Routes
- Topical, Transdermal
- Markets covered
- 3
- Products on record
- 197
- FDA reports (12 mo)
- 212
Overview
Plain-language summary, compiled from the cited regulatory records
Salicylic Acid is a topical medication classified as an Other Antifungal for Topical Use [1]. It is approved for use in treating acne, tightening the skin, moisturizing, improving the appearance of fine lines, and for whitening [1].
This active ingredient can be found in various products, including brand examples such as Quick Action, Clear Acne Spot Treatment, and Replenix Gly-Sal 10-2 cleanser [1]. In the past 12 months, there have been 212 adverse event reports associated with this ingredient [2]. The most frequently reported reactions include Irritable Bowel Syndrome, Decreased Joint Range of Motion, Joint Stiffness, Joint Dislocation, and Hypertension [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 162 | May 18, 2026 |
| GB United Kingdom | MHRA | 31 | April 24, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
USUnited States· FDA
162 products
Uses
Uses Anti-acne Tighten skin Moisturize Improve fine lines Whitening
How to take
GBUnited Kingdom· MHRA
31 products
Uses
For the treatment of corns, calluses, common warts and plantar warts (verrucas).
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Salicylic Acid. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 010029a3-8c1a-4f… · revised February 10, 2026 [PDF]
- [2]MHRA (UK) · PL560580003 · revised May 30, 2025
- [3]Health Canada (DPD) · 00266493 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.